Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Day One Biopharmaceuticals (DAWN) over the last 5 years, with Dec 2024 value amounting to -$231.0 million.

  • Day One Biopharmaceuticals' Cash from Investing Activities rose 119.88% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$262.5 million, marking a year-over-year decrease of 480.25%. This contributed to the annual value of -$231.0 million for FY2024, which is 279.93% down from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Cash from Investing Activities stood at -$231.0 million for FY2024, which was down 279.93% from $128.4 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Cash from Investing Activities registered a high of $128.4 million during FY2023, and its lowest value of -$255.1 million during FY2022.
  • Its 3-year average for Cash from Investing Activities is -$119.2 million, with a median of -$231.0 million in 2024.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Cash from Investing Activities crashed by 8,595.65% in 2021, and later skyrocketed by 150.33% in 2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Cash from Investing Activities (Yearly) stood at -$92,000 in 2020, then plummeted by 8,595.65% to -$8.0 million in 2021, then slumped by 3,088.43% to -$255.1 million in 2022, then skyrocketed by 150.33% to $128.4 million in 2023, then plummeted by 279.93% to -$231.0 million in 2024.